In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2641-2652

  Andrei, G ^a   Topalis, D ^a   Fiten, P ^a   McGuigan, C ^b   Balzarini, J ^a   Opdenakker, G ^a   Snoeck, R ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 6 (4 PENTYLPHENYL)FURO[2,3 D]PYRIMIDIN 2(3H)ONE; 3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 6 OCTYLFURO[2,3 D]PYRIMIDIN 2(3H) ONE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 6 (4 HEXYLPHENYL) 3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL]FURO[2,3 D]PYRIMIDIN 2(3H) ONE; 6 DECYL 3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2YL]THIENO[2,3 D]PYRIMIDIN 2(3H) ONE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR; PHOSPHONOACETIC ACID; PYRIMIDINE NUCLEOSIDE DERIVATIVE; SORIVUDINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DNA POLYMERASE GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; THYMIDINE KINASE GENE; VARICELLA ZOSTER VIRUS; VIRUS GENE; VIRUS MUTANT;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CELL LINE; DNA-DIRECTED DNA POLYMERASE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEOSIDES; PHENOTYPE; SEQUENCE ALIGNMENT; THYMIDINE KINASE; VIRAL PROTEINS;

HUMAN HERPESVIRUS 3;

EID: 84857868473     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06620-11     Document Type: Article

References (69)

1. Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. 2007. Managing herpes zoster in immunocompromised patients. Herpes 14:32-36.
2. Andrei G, De Clercq E, Snoeck R. 2004. In vitro selection of drugresistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res. 61:181-187.
3. Andrei G, et al. 2005. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides. Antimicrob. Agents Chemother. 49:1081-1086.
4. Andrei G, Snoeck R. 2011. Emerging drugs for varicella-zoster virus infections. Expert Opin. Emerg. Drugs 16:507-535.
5. Balzarini J, McGuigan C. 2002. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides. Biochim. Biophys. Acta 1587:287-295.
6. Balzarini J, et al. 2002. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol. Pharmacol. 61:1140-1145.
7. Bird LE, et al. 2003. Crystal structure of varicella zoster virus thymidine kinase. J. Biol. Chem. 278:24680-24687.
8. Boivin G, et al. 1994. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J. Infect. Dis. 170:68-75.
9. Breuer J, Whitley R. 2007. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 14(Suppl. 2):25-29.
10. Chouliaras G, Spoulou V, Quinlivan M, Breuer J, Theodoridou M. 2010. Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 125:e969-e972.
11. Crassard N, et al. 2000. Acyclovir-resistant varicella infection with atypical lesions in a non-HIV leukemic infant. Acta Paediatr. 89:1497-1499.
12. Earnshaw DL, et al. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36:2747-2757.
13. El Omari K, Liekens S, Bird LE, Balzarini J, Stammers DK. 2006. Mutations distal to the substrate site can affect varicella zoster virus thymidine kinase activity: implications for drug design. Mol. Pharmacol. 69:1891-1896.
14. Fillet AM, et al. 1998. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J. Med. Virol. 55:250-254.
15. Gardberg A, Shuvalova L, Monnerjahn C, Konrad M, Lavie A. 2003. Structural basis for the dual thymidine and thymidylate kinase activity of herpes thymidine kinases. Structure 11:1265-1277.
16. Gaudreau A, Hill E, Balfour HH, Jr, Erice A, Boivin G. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303.
17. Gershon AA. 2003. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J. Infect. Dis. 188:945-947.
18. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114.
19. Gnann JW, Jr. 2008. Vaccination to prevent herpes zoster in older adults. J. Pain 9:S31-S36.
20. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. 2008. Risk of herpes zoster in adults immunized with varicella vaccine. J. Infect. Dis. 197(Suppl. 2):S196 -S199.
21. Hatchette T, et al. 2008. Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr. Infect. Dis. J. 27:75-77.
22. Heininger U, Seward JF. 2006. Varicella. Lancet 368:1365-1376.
23. Hopfner KP, et al. 1999. Crystal structure of a thermostable type B DNA polymerase from Thermococcus gorgonarius. Proc. Natl. Acad. Sci. U. S. A. 96:3600-3605.
24. Ida M, et al. 1999. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. 40:155-166.
25. Jacobson MA, et al. 1990. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 112:187-191.
26. Kamiyama T, Kurokawa M, Shiraki K. 2001. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J. Gen. Virol. 82:2761-2765.
27. Kit S, et al. 1987. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob. Agents Chemother. 31:1483-1490.
28. Kodama E, Mori S, Shigeta S. 1995. Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine. Antiviral Res. 27:165-170.
29. Koyano S, Suzutani T, Yoshida I, Azuma M. 1996. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Antimicrob. Agents Chemother. 40:920-923.
30. Kramer JM, et al. 2001. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 108:E39.
31. Lacey SF, Suzutani T, Powell KL, Purifoy DJ, Honess RW. 1991. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction. J. Gen. Virol. 72:623-630.
32. Lee MY, Kim KS, Lee WK. 2011. Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. Ocul. Immunol. Inflamm. 19:212-213.
33. Levin MJ, et al. 2003. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J. Infect. Dis. 188:954-959.
34. Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L. 2010. Prevention strategies for herpes zoster and post-herpetic neuralgia. J. Clin. Virol. 48(Suppl. 1):S14 -S19.
35. Levy O, et al. 2003. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J. Infect. Dis. 188:948-953.
36. Linnemann CC, Jr, Biron KK, Hoppenjans WG, Solinger AM. 1990. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 4:577-579.
37. McGuigan C, Balzarini J. 2009. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J. Antimicrob. Chemother. 64:671-673.
38. McGuigan C, et al. 2007. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J. Antimicrob. Chemother. 60:1316-1330.
39. Mittal SK, Field HJ. 1989. Analysis of the bovine herpesvirus type 1 thymidine kinase (TK) gene from wild-type virus and TK-deficient mutants. J. Gen. Virol. 70:901-918.
40. Morfin F, et al. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182:290-293.
41. Morfin F, et al. 1999. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob. Agents Chemother. 43:2412-2416.
42. Pahwa S, et al. 1988. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 260:2879-2882.
43. Pentikis HS, et al. 2011. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob. Agents Chemother. 55:2847-2854.
44. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459-472.
45. Reardon JE, Spector T. 1989. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem. 264:7405-7411.
46. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. 2008. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J. Infect. Dis. 197(Suppl. 2):S224 -S227.
47. Roberts GB, Fyfe JA, Gaillard RK, Short SA. 1991. Mutant varicellazoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J. Virol. 65:6407-6413.
48. Safrin S, et al. 1991. Foscarnet therapy in five patients with AIDS and acyclovirresistant varicella-zoster virus infection. Ann. Intern. Med. 115:19-21.
49. Saint-Leger E, et al. 2001. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin. Infect. Dis. 33:2061-2067.
50. Sarisky RT, et al. 2001. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J. Virol. 75:1761-1769.
51. Sasadeusz JJ, et al. 1997. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J. Virol. 71:3872-3878.
52. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. 2010. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res. 86:246-252.
53. Sauerbrei A, Taut J, Zell R, Wutzler P. 2011. Resistance testing of clinical varicella-zoster virus strains. Antiviral Res. 90:242-247.
54. Schmader K. 2007. Herpes zoster and postherpetic neuralgia in older adults. Clin. Geriatr. Med. 23:615-632.
55. Schmader K, Gnann JW, Jr., Watson CP. 2008. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197(Suppl. 2):S207-S215.
56. Schmit I, Boivin G. 1999. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J. Infect. Dis. 180:487-490.
57. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX. 2006. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 64:301-307.
58. Snoeck R, et al. 1994. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J. Med. Virol. 42:338-347.
59. Steiner I, Kennedy PG, Pachner AR. 2007. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 6:1015-1028.
60. Suzutani T, et al. 2003. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob. Agents Chemother. 47:1707-1713.
61. Szpara ML, et al. 2011. A wide extent of inter-strain diversity in virulent and vaccine strains of alphaherpesviruses. PLoS Pathog. 7:e1002282.
62. Talarico CL, Phelps WC, Biron KK. 1993. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Virol. 67:1024-1033.
63. Tchesnokov EP, Obikhod A, Schinazi RF, Gotte M. 2009. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme. J. Biol. Chem. 284:26439-26446.
64. Thomas SL, Hall AJ. 2004. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect. Dis. 4:26-33.
65. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-L-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33:1765-1773.
66. Visse B, Dumont B, Huraux JM, Fillet AM. 1998. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J. Infect. Dis. 178(Suppl. 1):S55-S57.
67. Visse B, Huraux JM, Fillet AM. 1999. Point mutations in the varicellazoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J. Med. Virol. 59:84-90.
68. Whitley RJ, Gnann JW, Jr. 2009. Herpes zoster in the age of focused immunosuppressive therapy. JAMA 301:774-775.
69. Yamada S, Matsumoto Y, Takashima Y, Otsuka H. 2005. Mutation hot spots in the canine herpesvirus thymidine kinase gene. Virus Genes 31:107-111.